Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Authors: , Athena Philis-Tsimikas, David C. Klonoff, Kamlesh Khunti, Harpreet S. Bajaj, Lawrence A. Leiter, Melissa V. Hansen, Lone N. Troelsen, Steen Ladelund, Simon Heller, Thomas R. Pieber

Published: 2020-01-27

DOI: 10.1007/s00125-019-05080-9

Source: Full article

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Abstract